 DURHAM, N.C.--BUSINESS WIRE--Precision BioSciences, Inc. Nasdaq: DTIL, a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, today announced that the first patient has been dosed in its Phase 1 clinical trial with PBCAR19B, an immune evading allogeneic CAR T stealth cell candidate for patients with relapsedrefractory RR non-Hodgkin lymphoma NHL. We are excited to have dosed the first patient i 